Please ensure Javascript is enabled for purposes of website accessibility

Fate Therapeutics Snags $3 Billion-Plus Deal With Johnson & Johnson

By Brian Orelli, PhD - Apr 3, 2020 at 2:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The companies will be collaborating on immuno-oncology treatments.

On Thursday after the closing bell, Fate Therapeutics (FATE 0.99%) announced that it had gotten the backing of Johnson & Johnson's (JNJ -1.27%) Janssen Biotech division in a drug development deal that could be worth more than $3 billion ... if everything goes perfectly.

News of the agreement sent Fate's shares higher Friday. The stock was trading about 9% higher as of 2 p.m. EDT, while the broader market was down by more than 2%.

For now, Fate Therapeutics will get $50 million upfront and a $50 million investment from Johnson & Johnson. Its new partner will cover all the research and development costs on products targeting up to four different proteins expressed on cancerous cells, up to the filing of investigational new drug applications with the Food and Drug Administration. At that point, Johnson & Johnson can choose to license the therapies and take them through clinical development and commercialization. Fate will be responsible for producing the products, the cost of which will be covered by Johnson & Johnson.

Scientists working in a lab

Image source: Getty Images.

Fate will use its induced pluripotent stem cell (iPSC) technology to develop iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell products for the treatment of blood cancers and solid tumors. The deal covers the development of products targeting up to four different proteins expressed on cancerous cells.

Fate is eligible for up to $1.8 billion in development and regulatory milestone payments and up to $1.2 billion in commercial milestone payments, as well as double-digit royalties on sales of products from the collaboration. Fate can choose to co-promote any of the drugs in the U.S. and share equally in profits and losses in the U.S., but if Fate chooses that route, the biotech will have to pay for some of the clinical development costs and will get lower milestone and royalty payments on those drugs.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$168.50 (-1.27%) $-2.17
Fate Therapeutics, Inc. Stock Quote
Fate Therapeutics, Inc.
FATE
$32.74 (0.99%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.